Business Context and Reporting Period
Company: Glucotrack, Inc. (GCTK)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2025
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or general liquidity metrics. It details specific capital structure changes:
- Debt Converted: Approximately $4,093,112 (Note Investor) and $304,494 (July 18 Notes Holders).
- Shares Issued (Initial Conversion): 132,036 shares (Note Investor) and 9,760 shares (July 18 Notes Holders).
- Shares Issued (Warrant Exercise): 2,749,817 shares of Common Stock.
- Warrants Exchanged: 2,835,905 Series B Warrants.
Material Changes
The Company executed a significant equity transaction involving the conversion of debt and the cashless exercise of warrants:
- Debt-to-Equity Conversion: Converted outstanding principal and accrued interest from a Note Investor (controlled by a director) and three July 18 Notes into Common Stock, Series A Warrants, and Series B Warrants.
- Warrant Exercise: On March 11, 2025, the Note Investor and Holders exercised an alternative cashless feature on all held Series B Warrants. This resulted in the issuance of 2,749,817 additional shares of Common Stock.
- Valuation Impact: The cashless exercise formula allowed holders to acquire up to 300% of the shares available under a standard cash exercise.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the transactions were conducted pursuant to exemptions under Section 3(a)(9) of the Securities Act of 1933, as no additional consideration was delivered and no commissions were paid.
Risks/Contingencies: The filing does not provide forward-looking guidance, risk factors, or discussion of contingencies beyond the mechanics of the warrant exercise and debt conversion.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance of the 2,749,817 new shares.
- Confirm the dilution impact on existing shareholders resulting from the cashless warrant exercise.
- Review the terms of the remaining Series A Warrants and any other outstanding convertible debt.
- Check for subsequent filings regarding the impact of this capital raise on the Company's cash position and operational runway.